Diffuse Astrocytoma

Observed

→ investigated in trials for

Safusidenibsmall molecule

3 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bevacizumabmonoclonal antibody

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Carboplatinsmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Dabrafenibsmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Erlotinib Hydrochloridesmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Temsirolimussmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Trametinibsmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Alisertibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Atezolizumabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Erlotinibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Everolimussmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ipilimumabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Lutetium (177lu) Vipivotide Tetraxetanother

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nivolumabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Paclitaxelsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pembrolizumabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Perifosinesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Regorafenibsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Retifanlimabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sunitinibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Veliparibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Vincristinesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

Diffuse Astrocytoma studied in …STUDIED_INderived10 of 43show all (up to 200)
→ studied in	NCT06047379Phase 1/Phase 2 · recruiting Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis · condition mapped ALIAS · 43 trials mapped (15 active)	—	—	Astrocytoma, IDH-Mutant, Grade 2	1	Observed	clinicaltrials	graph →
→ studied in	NCT04729959Phase 2 · active not recruiting Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma · condition mapped ONTOLOGY_EXACT · 43 trials mapped (15 active)	—	—	Diffuse Astrocytoma, IDH-Wildtype	1	Observed	clinicaltrials	graph →
→ studied in	NCT03528642Phase 1 · active not recruiting Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma · condition mapped ONTOLOGY_EXACT · 43 trials mapped (15 active)	—	—	Astrocytoma, IDH-Mutant, Grade 2	1	Observed	clinicaltrials	graph →
→ studied in	NCT07703436Phase 2 · not yet recruiting Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease · condition mapped ONTOLOGY_EXACT · 43 trials mapped (15 active)	—	—	Astrocytoma, IDH-Mutant, Grade 2	1	Observed	clinicaltrials	graph →
→ studied in	NCT04065776NA · active not recruiting Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma · condition mapped CURATED_BROADER · 43 trials mapped (15 active)	—	—	Diffuse Astrocytoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06860594Phase 1 · recruiting Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma · condition mapped ONTOLOGY_EXACT · 43 trials mapped (15 active)	—	—	Astrocytoma, IDH-Mutant, Grade 2	1	Observed	clinicaltrials	graph →
→ studied in	NCT05303519Phase 3 · recruiting SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) · condition mapped ONTOLOGY_EXACT · 43 trials mapped (15 active)	—	—	Astrocytoma, IDH-Mutant, Grade 2	1	Observed	clinicaltrials	graph →
→ studied in	NCT03975829Phase 4 · active not recruiting Pediatric Long-Term Follow-up and Rollover Study · condition mapped CURATED_BROADER · 43 trials mapped (15 active)	—	—	Diffuse Astrocytoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03180502Phase 2 · active not recruiting Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma · condition mapped CURATED_BROADER · 43 trials mapped (15 active)	—	—	Diffuse Astrocytoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07712757Phase 3 · not yet recruiting Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma · condition mapped ONTOLOGY_EXACT · 43 trials mapped (15 active)	—	—	Astrocytoma, IDH-Mutant, Grade 2	1	Observed	clinicaltrials	graph →

Diffuse Astrocytoma studied in …STUDIED_INderived10 of 43show all (up to 200)

→ studied in

NCT06047379Phase 1/Phase 2 · recruiting

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis · condition mapped ALIAS · 43 trials mapped (15 active)

—

Observed

Diffuse Astrocytoma, IDH-Wildtype

→ studied in

NCT04729959Phase 2 · active not recruiting

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma · condition mapped ONTOLOGY_EXACT · 43 trials mapped (15 active)

—

Observed

→ studied in

NCT03528642Phase 1 · active not recruiting

Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma · condition mapped ONTOLOGY_EXACT · 43 trials mapped (15 active)

—

Observed

→ studied in

NCT07703436Phase 2 · not yet recruiting

Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease · condition mapped ONTOLOGY_EXACT · 43 trials mapped (15 active)

—

Observed

→ studied in

NCT04065776NA · active not recruiting

Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma · condition mapped CURATED_BROADER · 43 trials mapped (15 active)

—

Observed

→ studied in

NCT06860594Phase 1 · recruiting

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma · condition mapped ONTOLOGY_EXACT · 43 trials mapped (15 active)

—

Observed

→ studied in

NCT05303519Phase 3 · recruiting

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) · condition mapped ONTOLOGY_EXACT · 43 trials mapped (15 active)

—

Observed

→ studied in

NCT03975829Phase 4 · active not recruiting

Pediatric Long-Term Follow-up and Rollover Study · condition mapped CURATED_BROADER · 43 trials mapped (15 active)

—

Observed

→ studied in

NCT03180502Phase 2 · active not recruiting

Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma · condition mapped CURATED_BROADER · 43 trials mapped (15 active)

—

Observed

→ studied in

NCT07712757Phase 3 · not yet recruiting

Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma · condition mapped ONTOLOGY_EXACT · 43 trials mapped (15 active)

—

Observed